Getinge Posts Robust Q2 With Organic Growth And Margin Gains, Stock Up

Getinge AB (GETIb.ST) reported a strong Q2, with organic net sales up 4.1% and order intake rising 4.4%, despite a SEK 270 million tariff headwind. The company achieved an adjusted EBITA of SEK 989 million and SEK 4,183 million in adjusted gross profit, supported by sustained ventilator demand, high ECLS consumable orders, and accelerated Sterile Transfer life-science sales. Strategic initiatives like the earlier-than-expected EBITA boost from the Paragonix acquisition and a new Zimmer Biomet partnership expanding U.S. market reach further underscored performance, with free cash flow at SEK 510 million and the stock reacting positively, up 6.60%.

Analysis

Getinge AB delivered a robust second-quarter performance, demonstrating significant operational resilience by achieving 4.1% organic net sales growth and a 4.4% increase in order intake despite a SEK 270 million negative impact from tariffs. The company's profitability remained strong, with adjusted gross profit reaching SEK 4,183 million and adjusted EBITA at SEK 989 million, fueled by sustained demand for ventilators and ECLS consumables in its Acute Care Therapies division and accelerating sales in Sterile Transfer life-sciences. Strategic initiatives are already yielding positive results; the late-2024 acquisition of Paragonix contributed to EBITA ahead of schedule, and a new partnership with Zimmer Biomet provides a crucial entry point into the U.S. Ambulatory Surgery Center market for its Surgical Workflows division. The generation of SEK 510 million in free cash flow underscores the company's healthy financial position, which was met with a strong market endorsement, as evidenced by the 6.60% rise in its share price.

Key Decisions for Investors

• The combination of strong organic growth, resilient profitability despite tariff headwinds, and a positive 6.60% stock reaction supports a constructive outlook for current investors.
• Future growth appears underpinned by strategic execution, and investors should closely monitor the integration and sales momentum from the Paragonix acquisition and the market penetration achieved through the new Zimmer Biomet partnership.
• While Q2 results were strong, the SEK 270 million tariff impact highlights a key risk, and it is prudent to track ongoing currency and tariff developments as they could continue to pressure margins.